IRIDEX Corporation (IRIX) Stock: Price, Forecast & Analyst Target
IRIDEX Corporation (IRIX) — price $0.7561 (+1.39%), as of the Oct 26, 2026 trading session; market cap $13.3M.
Educational signal · not a buy or sell recommendation · How to read this
IRIDEX Corporation · IRIX · NASDAQ
IRIDEX Corporation develops and markets ophthalmic laser systems, delivery devices, and consumable instrumentation. Their products are used to treat sight-threatening eye diseases such as glaucoma and diabetic macular edema.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.7561 | |
| Change on the day | +1.39% | |
| 52-week range | $0.607 – $1.65 | |
| Market capitalisation | $13.3M | |
| Shares traded on the day | 6.9K |
Price & events
Other perspectives
Council score for IRIDEX (IRIX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the IRIX film — every key number, told as a short cinematic story
~2 min · open the film
What is IRIDEX (IRIX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. IRIDEX Corporation (IRIX) is listed on NASDAQ. It employs 93 people and is led by Patrick Mercer. In Q2 FY2026 it reported revenue of $13M and net income of -$1M. The market values it at $13.3M.
What do the latest results show for IRIDEX (IRIX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $13M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $13M | -$1M | -$0.07 (diluted) |
| Q1 FY2026 | $12M | -$524,000 | -$0.03 (diluted) |
| Q4 FY2025 | $15M | -$184,000 | -$0.01 (diluted) |
| Q3 FY2025 | $12M | -$2M | -$0.09 (diluted) |
What are the financial strengths and risks for IRIDEX (IRIX)?
Short answer
The distress and quality screens read Altman Z -2.53 · Piotroski F 3. Trailing ratios: ROE -64.2% · ROA -11.6% · current ratio 1.92 · earnings yield -16.5% · free-cash-flow yield -12.3%.
Data-derived red flags
- Listing risk — at $0.7561 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -2.53 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-64.2%) — the business is not currently generating profit on shareholder capital.
What should you watch next at IRIDEX (IRIX)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $52.52M · EPS -0.12 · 1 analysts. Current published price targets run low $2.75 · high $2.75 · consensus $2.75 · median $2.75 against a quoted price of $0.7561 (as of Oct 26, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $2.75 – $2.75
- Consensus target
- $2.75
- Median target
- $2.75
- Revenue estimate
- $52.52M
- EPS estimate
- $-0.12
Consensus record · Captured .
Measured against a quoted price of $0.7561 (as of Oct 26, 2026).
Common Questions About IRIX
These answers are editorial: 1 of these 8 answers is drawn from the IRIX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IRIX a good stock to buy?
Stock Expert AI does not rate IRIX buy, sell or hold. IRIDEX Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IRIX stock price today?
The last price recorded on this page for IRIDEX Corporation (IRIX) is $0.7561, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IRIX price target?
The analyst consensus price target for IRIDEX Corporation (IRIX) is $2.75 (range $2.75 to $2.75, median $2.75), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about IRIX stock?
Analyst coverage of IRIDEX Corporation (IRIX) is limited, reflecting its small-cap status. However, general sentiment suggests a focus on the company's growth potential within the ophthalmic medical device market. Key valuation metrics, such as price-to-sales ratio, are often considered in relation to its growth prospects. Investors monitor the company's ability to improve its profit margin and expand its market share.
What are the key factors to evaluate for IRIX?
Evaluate IRIX on fundamentals, analyst consensus, and risk factors. Analysts target $2.75 (+264%). Focus on glaucoma and retinal disease treatments positions the company in a growing market segment. Not financial advice.
How frequently does IRIX data refresh on this page?
IRIX's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IRIX's recent stock price performance?
IRIDEX Corporation (IRIX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized laser technology for ophthalmic applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IRIX overvalued or undervalued right now?
IRIDEX Corporation (IRIX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $2.75 (+264%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (21 figures)
The 21 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 12 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.7561 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T15:44:43.231Z. | |
px.change | Change on the day | +1.39% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $13.3M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T15:40:27.000Z. Captured from FMP at 2026-10-26T15:44:41.309Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.0104 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 6.9K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $13M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $2.75 · high $2.75 · consensus $2.75 · median $2.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $2.75 – $2.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $2.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $2.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.607 – $1.65 | UNRECORDED | Stored company-profile observation — Captured 2026-10-21 | |
id.employees | Employees | 93 | UNRECORDED | Stored company-profile observation — Captured 2026-10-21 | |
id.ceo | Chief executive | Patrick Mercer | UNRECORDED | Stored company-profile observation — Captured 2026-10-21 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -2.53 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -64.2% · ROA -11.6% · current ratio 1.92 · earnings yield -16.5% · free-cash-flow yield -12.3% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $52.52M · EPS -0.12 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-08-21 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $52.52M | UNRECORDED | Stored analyst estimates — Captured 2026-08-21 · Expired observation | |
earn.est_eps | EPS estimate, FY2027 | $-0.12 | UNRECORDED | Stored analyst estimates — Captured 2026-08-21 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.